Skip to main content

Table 3 List of local pathways in PathVisio significantly affected by the celecoxib treatment.

From: A randomised controlled phase II trial of pre-operative celecoxib treatment reveals anti-tumour transcriptional response in primary breast cancer

MAPP Name

number

changed

number

measured

% changed

Z-scorea

Up-regulated

Complement and coagulation cascades

15

50

30.00%

5.65

Senescence and autophagy

18

100

18.00%

3.61

RANKL/RANK signalling pathway

11

50

22.00%

3.58

Complement activation, classical pathway

5

15

33.33%

3.55

Matrix metalloproteinases

7

29

24.14%

3.14

TGF beta signalling pathway

18

113

15.93%

3.03

Inflammatory response pathway

7

30

23.33%

3.03

Oxidative stress

6

24

25.00%

3.01

Adipogenesis

19

125

15.20%

2.89

Endochondral ossification

11

61

18.03%

2.82

TWEAK signalling pathway

8

40

20.00%

2.73

SREBP signalling

6

28

21.43%

2.56

Down-regulated

    

Cell cycle

17

95

17.89%

6.62

DNA replication

9

41

21.95%

5.61

Nucleotide metabolism

5

17

29.41%

5.12

Proteasome degradation

10

57

17.54%

4.97

Electron transport chain

10

81

12.35%

3.61

G1 to S cell cycle control

7

67

10.45%

2.51

  1. aZ-score is the standard statistical test under the hypergeometric distribution; pathways ranked by Z-score. Z-score > 1.96 (corresponding to P-value = 0.05) and at least five, but less than 150 genes meeting the criterion are shown. TGF, tumour growth factor.